Pharmacological characterization of 1-nitrosocyclohexyl acetate, a long-acting nitroxyl donor that shows vasorelaxant and antiaggregatory effects

Journal of Pharmacology and Experimental Therapeutics

Volumn 344, Issue 2, 2013, Pages 339-347

  Donzelli, Sonia ^a,b,c   Fischer, Gerry ^a,b   King, Bruce S ^d   Niemann, Christin ^b   DuMond, Jenna F ^d   Heeren, Jörg ^b   Wieboldt, Hartwig ^e   Baldus, Stephan ^c,e   Gerloff, Christian ^b   Eschenhagen, Thomas ^a,c   Carrier, Lucie ^a,c,f   Böger, Rainer H ^b,c   Espey, Michael Graham ^g,h  

^a UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^b Department of Neurology ^*  (Germany)

^c Research Center   (Germany)

^d RUHR UNIVERSITY BOCHUM   (Germany)

^e WAKE FOREST UNIVERSITY   (United States)

^f UNIVERSITY HEART CENTER HAMBURG   (Germany)

^g INSERM   (France)

^h NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1 NITROSOCYCLOHEXYL ACETATE; 15 HYDROXY 11ALPHA,9ALPHA EPOXYMETHANOPROSTA 5,13 DIENOIC ACID; ADENOSINE TRIPHOSPHATE SENSITIVE POTASSIUM CHANNEL; ADENYLATE CYCLASE; CALCITONIN GENE RELATED PEPTIDE RECEPTOR; CALCIUM ACTIVATED POTASSIUM CHANNEL; CYCLIC GMP; GLUTATHIONE; GUANYLATE CYCLASE; NITRIC OXIDE DONOR; THROMBOXANE A2; UNCLASSIFIED DRUG; VOLTAGE GATED POTASSIUM CHANNEL;

ANIMAL TISSUE; ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG MECHANISM; DRUG PROTEIN BINDING; DRUG TARGETING; EXPERIMENTAL MOUSE; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; THROMBOCYTE AGGREGATION INHIBITION; VASCULAR ENDOTHELIUM; VASCULAR RING; VASODILATATION; WILD TYPE;

ACETATES; ANIMALS; AORTA, THORACIC; APOLIPOPROTEINS E; ATHEROSCLEROSIS; BLOOD PLATELETS; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; ENDOTHELIUM, VASCULAR; HALF-LIFE; HUMANS; MICE; MICE, INBRED C57BL; NITRIC OXIDE DONORS; NITROGEN OXIDES; NITROSO COMPOUNDS; PLATELET AGGREGATION; PLATELET AGGREGATION INHIBITORS; VASODILATION; VASODILATOR AGENTS;

EID: 84872731281     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.112.199836     Document Type: Article

References (60)

1. Andrews KL, Irvine JC, Tare M, Apostolopoulos J, Favaloro JL, Triggle CR, and Kemp-Harper BK (2009) A role for nitroxyl (HNO) as an endothelium-derived relaxing and hyperpolarizing factor in resistance arteries. Br J Pharmacol 157: 540-550.
2. Bermejo E, Sáenz DA, Alberto F, Rosenstein RE, Bari SE, and Lazzari MA (2005) Effect of nitroxyl on human platelets function. Thromb Haemost 94:578-584. (Pubitemid 41300855)
3. Bullen ML, Miller AA, Andrews KL, Irvine JC, Ritchie RH, Sobey CG, and Kemp- Harper BK (2011a) Nitroxyl (HNO) as a vasoprotective signaling molecule. Antioxid Redox Signal 14:1675-1686.
4. Bullen ML, Miller AA, Dharmarajah J, Drummond GR, Sobey CG, and Kemp-Harper BK (2011b) Vasorelaxant and antiaggregatory actions of the nitroxyl donor isopropylamine NONOate are maintained in hypercholesterolemia. Am J Physiol Heart Circ Physiol 301:H1405-H1414.
5. Cheong E, Tumbev V, Abramson J, Salama G, and Stoyanovsky DA (2005) Nitroxyl triggers Ca21 release from skeletal and cardiac sarcoplasmic reticulum by oxidizing ryanodine receptors. Cell Calcium 37:87-96. (Pubitemid 39497152)
6. Choe CU, Lewerenz J, Fischer G, Uliasz TF, Espey MG, Hummel FC, King SB, Schwedhelm E, Böger RH, and Gerloff C, et al. (2009) Nitroxyl exacerbates ischemic cerebral injury and oxidative neurotoxicity. J Neurochem 110:1766-1773.
7. Coleman R, Hayek T, Keidar S, and Aviram M (2006) A mouse model for human atherosclerosis: long-term histopathological study of lesion development in the aortic arch of apolipoprotein E-deficient (E0) mice. Acta Histochem 108:415-424. (Pubitemid 44708294)
8. Cordaillat M, Fort A, Virsolvy A, Elghozi JL, Richard S, and Jover B (2007) Nitric oxide pathway counteracts enhanced contraction to membrane depolarization in aortic rings of rats on high-sodium diet. Am J Physiol Regul Integr Comp Physiol 292:R1557-R1562. (Pubitemid 46557819)
9. Dai T, Tian Y, Tocchetti CG, Katori T, Murphy AM, Kass DA, Paolocci N, and Gao WD (2007) Nitroxyl increases force development in rat cardiac muscle. J Physiol 580:951-960. (Pubitemid 46909044)
10. De Witt BJ, Marrone JR, Kaye AD, Keefer LK, and Kadowitz PJ (2001) Comparison of responses to novel nitric oxide donors in the feline pulmonary vascular bed. Eur J Pharmacol 430:311-315. (Pubitemid 33050056)
11. Eikelboom JW, Hirsh J, Weitz JI, Johnston M, Yi Q, and Yusuf S (2002) Aspirinresistant thromboxane biosynthesis and the risk of myocardial infarction, stroke, or cardiovascular death in patients at high risk for cardiovascular events. Circulation 105:1650-1655. (Pubitemid 34298607)
12. El-Armouche A and Eschenhagen T (2009) Beta-adrenergic stimulation and myocardial function in the failing heart. Heart Fail Rev 14:225-241.
13. El-Armouche A, Wahab A, Wittköpper K, Schulze T, Böttcher F, Pohlmann L, King SB, DuMond JF, Gerloff C, and Böger RH, et al. (2010) The new HNO donor, 1- nitrosocyclohexyl acetate, increases contractile force in normal and b-adrenergically desensitized ventricular myocytes. Biochem Biophys Res Commun 402: 340-344.
14. Ellis A, Li CG, and Rand MJ (2000) Differential actions of L-cysteine on responses to nitric oxide, nitroxyl anions and EDRF in the rat aorta. Br J Pharmacol 129: 315-322. (Pubitemid 30072652)
15. Espey MG, Miranda KM, Thomas DD, and Wink DA (2002) Ingress and reactive chemistry of nitroxyl-derived species within human cells. Free Radic Biol Med 33: 827-834. (Pubitemid 35232317)
16. Favaloro JL and Kemp-Harper BK (2007) The nitroxyl anion (HNO) is a potent dilator of rat coronary vasculature. Cardiovasc Res 73:587-596. (Pubitemid 46073951)
17. Favaloro JL and Kemp-Harper BK (2009) Redox variants of NO (NO(.) and HNO) elicit vasorelaxation of resistance arteries via distinct mechanisms. Am J Physiol Heart Circ Physiol 296:H1274-H1280.
18. Froehlich JP, Mahaney JE, Keceli G, Pavlos CM, Goldstein R, Redwood AJ, Sumbilla C, Lee DI, Tocchetti CG, and Kass DA, et al. (2008) Phospholamban thiols play a central role in activation of the cardiac muscle sarcoplasmic reticulum calcium pump by nitroxyl. Biochemistry 47:13150-13152.
19. Fukuto JM, Chiang K, Hszieh R, Wong P, and Chaudhuri G (1992) The pharmacological activity of nitroxyl: a potent vasodilator with activity similar to nitric oxide and/or endothelium-derived relaxing factor. J Pharmacol Exp Ther 263:546-551.
20. Gao WD, Murray CI, Tian Y, Zhong X, DuMond JF, Shen X, Stanley BA, Foster DB, Wink DA, and King SB, et al. (2012) Nitroxyl-mediated disulfide bond formation between cardiac myofilament cysteines enhances contractile function. Circ Res 111:1002-1011.
21. Haba M, Kinoshita H, Matsuda N, Azma T, Hama-Tomioka K, Hatakeyama N, Yamazaki M, and Hatano Y (2009) Beneficial effect of propofol on arterial adenosine triphosphate-sensitive K1 channel function impaired by thromboxane. Anesthesiology 111:279-286.
22. Hu CP, Xiao L, Deng HW, and Li YJ (2003) The depressor and vasodilator effects of rutaecarpine are mediated by calcitonin gene-related peptide. Planta Med 69: 125-129. (Pubitemid 36384495)
23. Irvine JC, Favaloro JL, and Kemp-Harper BK (2003) NO- activates soluble guanylate cyclase and Kv channels to vasodilate resistance arteries. Hypertension 41: 1301-1307. (Pubitemid 36706081)
24. Irvine JC, Favaloro JL, Widdop RE, and Kemp-Harper BK (2007) Nitroxyl anion donor, Angeli's salt, does not develop tolerance in rat isolated aortae. Hypertension 49:885-892. (Pubitemid 351664199)
25. Irvine JC, Ritchie RH, Favaloro JL, Andrews KL, Widdop RE, and Kemp-Harper BK (2008) Nitroxyl (HNO): the Cinderella of the nitric oxide story. Trends Pharmacol Sci 29:601-6078.
26. Jiang J, Thorén P, Caligiuri G, Hansson GK, and Pernow J (1999) Enhanced phenylephrine-induced rhythmic activity in the atherosclerotic mouse aorta via an increase in opening of KCa channels: relation to Kv channels and nitric oxide. Br J Pharmacol 128:637-646. (Pubitemid 29504754)
27. Katori T, Hoover DB, Ardell JL, Helm RH, Belardi DF, Tocchetti CG, Forfia PR, Kass DA, and Paolocci N (2005) Calcitonin gene-related peptide in vivo positive inotropy is attributable to regional sympatho-stimulation and is blunted in congestive heart failure. Circ Res 96:234-243. (Pubitemid 40209371)
28. Leo CH, Joshi A, Hart JL, and Woodman OL (2012) Endothelium-dependent nitroxylmediated relaxation is resistant to superoxide anion scavenging and preserved in diabetic rat aorta. Pharmacol Res 66:383-391.
29. Lin EQ, Irvine JC, Cao AH, Alexander AE, Love JE, Patel R, McMullen JR, Kaye DM, Kemp-Harper BK, and Ritchie RH (2012) Nitroxyl (HNO) stimulates soluble guanylyl cyclase to suppress cardiomyocyte hypertrophy and superoxide generation. PLoS ONE 7:e34892.
30. Lunardi CN, Vercesi JA, da Silva RS, and Bendhack LM (2007) Vasorelaxation induced by the new nitric oxide donor cis-[Ru(Cl)(bpy)(2)(NO)] (PF(6)) is due to activation of K(Ca) by a cGMP-dependent pathway. Vascul Pharmacol 47:139-144. (Pubitemid 47095452)
31. Ma XL, Gao F, Liu GL, Lopez BL, Christopher TA, Fukuto JM, Wink DA, and Feelisch M (1999) Opposite effects of nitric oxide and nitroxyl on postischemic myocardial injury. Proc Natl Acad Sci USA 96:14617-14622. (Pubitemid 30000699)
32. Mehta JL, Lawson D, Mehta P, and Saldeen T (1988) Increased prostacyclin and thromboxane A2 biosynthesis in atherosclerosis. Proc Natl Acad Sci USA 85: 4511-4515.
33. Miller TW, Cherney MM, Lee AJ, Francoleon NE, Farmer PJ, King SB, Hobbs AJ, Miranda KM, Burstyn JN, and Fukuto JM (2009) The effects of nitroxyl (HNO) on soluble guanylate cyclase activity: interactions at ferrous heme and cysteine thiols. J Biol Chem 284:21788-21796.
34. Miranda KM, Katori T, Torres de Holding CL, Thomas L, Ridnour LA, McLendon WJ, Cologna SM, Dutton AS, Champion HC, and Mancardi D, et al. (2005a) Comparison of the NO and HNO donating properties of diazeniumdiolates: primary amine adducts release HNO in vivo. J Med Chem 48:8220-82278.
35. Miranda KM, Nagasawa HT, and Toscano JP (2005b) Donors of HNO. Curr Top Med Chem 5:649-664. (Pubitemid 41179725)
36. Miranda KM, Nims RW, Thomas DD, Espey MG, Citrin D, Bartberger MD, Paolocci N, Fukuto JM, Feelisch M, and Wink DA (2003a) Comparison of the reactivity of nitric oxide and nitroxyl with heme proteins. A chemical discussion of the differential biological effects of these redox related products of NOS. J Inorg Biochem 93: 52-60. (Pubitemid 36132133)
37. Miranda KM, Paolocci N, Katori T, Thomas DD, Ford E, Bartberger MD, Espey MG, Kass DA, Feelisch M, and Fukuto JM, et al. (2003b) A biochemical rationale for the discrete behavior of nitroxyl and nitric oxide in the cardiovascular system. Proc Natl Acad Sci USA 100:9196-9201. (Pubitemid 37033906)
38. Miranda KM, Yamada K, Espey MG, Thomas DD, DeGraff W, Mitchell JB, Krishna MC, Colton CA, and Wink DA (2002) Further evidence for distinct reactive intermediates from nitroxyl and peroxynitrite: effects of buffer composition on the chemistry of Angeli's salt and synthetic peroxynitrite. Arch Biochem Biophys 401:134-144. (Pubitemid 34848615)
39. Moncada S and Higgs EA (1987) Prostaglandins in the pathogenesis and prevention of vascular disease. Blood Rev 1:141-145.
40. Mondoro TH, Ryan BB, Hrinczenko BW, Schechter AN, Vostal JG, and Alayash AI (2001) Biological action of nitric oxide donor compounds on platelets from patients with sickle cell disease. Br J Haematol 112:1048-1054. (Pubitemid 32322935)
41. Morello S, Vellecco V, Alfieri A, Mascolo N, and Cicala C (2006) Vasorelaxant effect of the flavonoid galangin on isolated rat thoracic aorta. Life Sci 78:825-830. (Pubitemid 43082305)
42. Paolocci N, Jackson MI, Lopez BE, Miranda K, Tocchetti CG, Wink DA, Hobbs AJ, and Fukuto JM (2007) The pharmacology of nitroxyl (HNO) and its therapeutic potential: not just the Janus face of NO. Pharmacol Ther 113:442-4578.
43. Paolocci N, Katori T, Champion HC, St John ME, Miranda KM, Fukuto JM, Wink DA, and Kass DA (2003) Positive inotropic and lusitropic effects of HNO/NO- in failing hearts: independence from beta-adrenergic signaling. Proc Natl Acad Sci USA 100:5537-5542. (Pubitemid 36542740)
44. Paolocci N, Saavedra WF, Miranda KM, Martignani C, Isoda T, Hare JM, Espey MG, Fukuto JM, Feelisch M, and Wink DA, et al. (2001) Nitroxyl anion exerts redoxsensitive positive cardiac inotropy in vivo by calcitonin gene-related peptide signaling. Proc Natl Acad Sci USA 98:10463-104678.
45. Pino RZ and Feelisch M (1994) Bioassay discrimination between nitric oxide (NO.) and nitroxyl (NO-) using L-cysteine. Biochem Biophys Res Commun 201:54-62.
46. Saldeen P, Nilsson IM, and Saldeen T (1983) Increased synthesis of thromboxane B2 and 6-keto-PGF1 alpha in hand veins from patients with deep venous thrombosis. Thromb Res 32:461-467. (Pubitemid 14243217)
47. Sha X, Isbell TS, Patel RP, Day CS, and King SB (2006) Hydrolysis of acyloxy nitroso compounds yields nitroxyl (HNO). J Am Chem Soc 128:9687-9692. (Pubitemid 44147951)
48. Shafiei M and Mahmoudian M (1999) Atypical beta-adrenoceptors of rat thoracic aorta. Gen Pharmacol 32:557-562. (Pubitemid 29219457)
49. Shieh CC, Coghlan M, Sullivan JP, and Gopalakrishnan M (2000) Potassium channels: molecular defects, diseases, and therapeutic opportunities. Pharmacol Rev 52:557-594.
50. Shoman ME, DuMond JF, Isbell TS, Crawford JH, Brandon A, Honovar J, Vitturi DA, White CR, Patel RP, and King SB (2011) Acyloxy nitroso compounds as nitroxyl (HNO) donors: kinetics, reactions with thiols, and vasodilation properties. J Med Chem 54:1059-1070.
51. Switzer CH, Flores-Santana W, Mancardi D, Donzelli S, Basudhar D, Ridnour LA, Miranda KM, Fukuto JM, Paolocci N, and Wink DA (2009) The emergence of nitroxyl (HNO) as a pharmacological agent. Biochim Biophys Acta 1787:835-840.
52. Tocchetti CG, Stanley BA, Murray CI, Sivakumaran V, Donzelli S, Mancardi D, Pagliaro P, Gao WD, van Eyk J, and Kass DA, et al. (2011) Playing with cardiac "redox switches": the "HNO way" to modulate cardiac function. Antioxid Redox Signal 14:1687-16978.
53. Tocchetti CG, Wang W, Froehlich JP, Huke S, Aon MA, Wilson GM, Di Benedetto G, O'Rourke B, Gao WD, and Wink DA, et al. (2007) Nitroxyl improves cellular heart function by directly enhancing cardiac sarcoplasmic reticulum Ca21 cycling. Circ Res 100:96-104. (Pubitemid 46066777)
54. Vanhoutte PM, Shimokawa H, Tang EH, and Feletou M (2009) Endothelial dysfunction and vascular disease. Acta Physiol (Oxf) 196:193-222.
55. Wang GR, Zhu Y, Halushka PV, Lincoln TM, and Mendelsohn ME (1998) Mechanism of platelet inhibition by nitric oxide: in vivo phosphorylation of thromboxane receptor by cyclic GMP-dependent protein kinase. Proc Natl Acad Sci USA 95: 4888-4893. (Pubitemid 28208520)
56. Wanstall JC, Jeffery TK, Gambino A, Lovren F, and Triggle CR (2001) Vascular smooth muscle relaxation mediated by nitric oxide donors: a comparison with acetylcholine, nitric oxide and nitroxyl ion. Br J Pharmacol 134:463-472. (Pubitemid 32977891)
57. Wynne BM, Labazi H, Tostes RC, and Webb RC (2012) Aorta from angiotensin II hypertensive mice exhibit preserved nitroxyl anion mediated relaxation responses. Pharmacol Res 65:41-47.
58. Zeller A, Wenzl MV, Beretta M, Stessel H, Russwurm M, Koesling D, Schmidt K, and Mayer B (2009) Mechanisms underlying activation of soluble guanylate cyclase by the nitroxyl donor Angeli's salt. Mol Pharmacol 76:1115-1122.
59. Zgheib C, Kurdi M, Zouein FA, Gunter BW, Stanley BA, Zgheib J, Romero DG, King SB, Paolocci N, and Booz GW (2012) Acyloxy nitroso compounds inhibit LIF signaling in endothelial cells and cardiac myocytes: evidence that STAT3 signaling is redox-sensitive. PLoS ONE 7:e43313.
60. Zhang SH, Reddick RL, Piedrahita JA, and Maeda N (1992) Spontaneous hypercholesterolemia and arterial lesions in mice lacking apolipoprotein E. Science 258: 468-471.